JSE-listed Life Healthcare Group, through its wholly owned indirect subsidiary in the  UK, Life Medical Group Limited (LMGL), has entered into binding agreements with Lantheus Neurology UK, a wholly owned subsidiary of Lantheus Holdings for the sale of 100% of the issued share capital of LMI Limited and its subsidiaries, collectively known as Life Molecular Imaging (LMI). The total purchase consideration of $750-million, about R13.9-billion, includes an upfront payment of $350-million and earnouts totalling a further $400-million, contingent on achieving future milestone sales of LMI products through to 2034.